AZN vs. NFLX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and NFLX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AZN’s market capitalization stands at 430.65 billion USD, while NFLX’s is 552.04 billion USD, indicating their market valuations are broadly comparable.
NFLX carries a higher beta at 1.59, indicating it’s more sensitive to market moves, while AZN (beta: 0.17) exhibits greater stability.
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, NFLX is a standard domestic listing.
| Symbol | AZN | NFLX |
|---|---|---|
| Company Name | AstraZeneca PLC | Netflix, Inc. |
| Country | GB | US |
| Sector | Healthcare | Communication Services |
| Industry | Drug Manufacturers - General | Entertainment |
| CEO | Pascal Claude Roland Soriot | Theodore A. Sarandos |
| Price | 69.45 USD | 1,297.18 USD |
| Market Cap | 430.65 billion USD | 552.04 billion USD |
| Beta | 0.17 | 1.59 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 12, 1993 | May 23, 2002 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of AZN and NFLX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AZN
19.18%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
AZN’s Return on Equity of 19.18% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
NFLX
39.61%
Entertainment Industry
- Max
- 52.68%
- Q3
- 19.21%
- Median
- 2.19%
- Q1
- -9.02%
- Min
- -38.07%
In the upper quartile for the Entertainment industry, NFLX’s Return on Equity of 39.61% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
AZN
10.93%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AZN’s Return on Invested Capital of 10.93% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
NFLX
22.23%
Entertainment Industry
- Max
- 22.23%
- Q3
- 7.94%
- Median
- 4.38%
- Q1
- -1.64%
- Min
- -11.28%
In the upper quartile for the Entertainment industry, NFLX’s Return on Invested Capital of 22.23% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
AZN
14.14%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AZN’s Net Profit Margin of 14.14% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
NFLX
23.09%
Entertainment Industry
- Max
- 23.09%
- Q3
- 7.10%
- Median
- 4.00%
- Q1
- -5.55%
- Min
- -19.16%
A Net Profit Margin of 23.09% places NFLX in the upper quartile for the Entertainment industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
AZN
19.21%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AZN’s Operating Profit Margin of 19.21% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
NFLX
27.65%
Entertainment Industry
- Max
- 27.65%
- Q3
- 14.60%
- Median
- 8.91%
- Q1
- -1.50%
- Min
- -17.48%
An Operating Profit Margin of 27.65% places NFLX in the upper quartile for the Entertainment industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AZN | NFLX |
|---|---|---|
| Return on Equity (TTM) | 19.18% | 39.61% |
| Return on Assets (TTM) | 7.31% | 17.80% |
| Return on Invested Capital (TTM) | 10.93% | 22.23% |
| Net Profit Margin (TTM) | 14.14% | 23.09% |
| Operating Profit Margin (TTM) | 19.21% | 27.65% |
| Gross Profit Margin (TTM) | 81.41% | 46.87% |
Financial Strength
Current Ratio
AZN
0.90
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AZN’s Current Ratio of 0.90 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
NFLX
1.20
Entertainment Industry
- Max
- 2.86
- Q3
- 1.51
- Median
- 0.84
- Q1
- 0.46
- Min
- 0.26
NFLX’s Current Ratio of 1.20 aligns with the median group of the Entertainment industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
AZN
0.77
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
AZN’s Debt-to-Equity Ratio of 0.77 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NFLX
0.73
Entertainment Industry
- Max
- 10.61
- Q3
- 5.84
- Median
- 0.94
- Q1
- 0.71
- Min
- 0.01
NFLX’s Debt-to-Equity Ratio of 0.73 is typical for the Entertainment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
AZN
7.95
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
AZN’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
NFLX
14.77
Entertainment Industry
- Max
- 7.49
- Q3
- 3.71
- Median
- 1.58
- Q1
- -0.42
- Min
- -5.05
With an Interest Coverage Ratio of 14.77, NFLX demonstrates a superior capacity to service its debt, placing it well above the typical range for the Entertainment industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | AZN | NFLX |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 1.20 |
| Quick Ratio (TTM) | 0.70 | 1.20 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 0.73 |
| Debt-to-Asset Ratio (TTM) | 0.30 | 0.33 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.49 | 0.38 |
| Interest Coverage Ratio (TTM) | 7.95 | 14.77 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AZN and NFLX. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AZN
1.87%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AZN’s Dividend Yield of 1.87% is in the lower quartile for the Drug Manufacturers - General industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
NFLX
0.00%
Entertainment Industry
- Max
- 7.41%
- Q3
- 0.95%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NFLX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
AZN
63.60%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 63.60% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
NFLX
0.00%
Entertainment Industry
- Max
- 82.73%
- Q3
- 7.88%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NFLX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AZN | NFLX |
|---|---|---|
| Dividend Yield (TTM) | 1.87% | 0.00% |
| Dividend Payout Ratio (TTM) | 63.60% | 0.00% |
Valuation
Price-to-Earnings Ratio
AZN
28.12
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
At 28.12, AZN’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
NFLX
59.79
Entertainment Industry
- Max
- 85.23
- Q3
- 70.18
- Median
- 35.61
- Q1
- 19.80
- Min
- 6.95
NFLX’s P/E Ratio of 59.79 is within the middle range for the Entertainment industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
AZN
2.56
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AZN’s Forward PEG Ratio of 2.56 is within the middle range of its peers in the Drug Manufacturers - General industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
NFLX
3.36
Entertainment Industry
- Max
- 5.10
- Q3
- 2.63
- Median
- 1.23
- Q1
- 0.35
- Min
- 0.06
A Forward PEG Ratio of 3.36 places NFLX in the upper quartile for the Entertainment industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
AZN
3.98
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AZN’s P/S Ratio of 3.98 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
NFLX
13.75
Entertainment Industry
- Max
- 4.71
- Q3
- 2.84
- Median
- 1.46
- Q1
- 0.70
- Min
- 0.27
With a P/S Ratio of 13.75, NFLX trades at a valuation that eclipses even the highest in the Entertainment industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
AZN
5.33
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
NFLX
23.07
Entertainment Industry
- Max
- 11.55
- Q3
- 8.75
- Median
- 2.23
- Q1
- 1.18
- Min
- 0.51
The P/B Ratio is often not a primary valuation metric for the Entertainment industry.
Valuation at a Glance
| Symbol | AZN | NFLX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.12 | 59.79 |
| Forward PEG Ratio (TTM) | 2.56 | 3.36 |
| Price-to-Sales Ratio (P/S, TTM) | 3.98 | 13.75 |
| Price-to-Book Ratio (P/B, TTM) | 5.33 | 23.07 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.59 | 74.14 |
| EV-to-EBITDA (TTM) | 13.82 | 21.07 |
| EV-to-Sales (TTM) | 4.46 | 14.01 |